Galea Therapeutics

Our molecule reverts Fatty Liver Disease by reducing liver fat by 41%, fat biosynthesis by 35%, liver cell apoptosis by 89% and excessive food intake by 48%.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Madrid, Spain
  • Currency EUR
  • Founded October 2018
  • Employees 3
  • Incorporation Type C-corp
  • Website galeatherapeutics.com

Company Summary

Fatty Liver disease is a looming global epidemic affecting one out of every four adults and resulting in a € 543 economic burden.

Our drug candidate is the only one capable of reverting this disease while stopping the originating cause at the same time.

We have a solid pipeline of drug candidates addressing NASH, ASH and AUD.

Team

  • Pablo Inones

  • Ruben Henriquez
    COO

    Business strategist and manager with significant experience in design, launch and growth of Biopharma projects and companies.
    Track record of fundraising for biotechs and negotiation of licenses and alliances between Universities, Biotech and Big Pharma.
    Corporate R&D Project Manager- Novartis and Sandoz (Switzerland).

  • Fernando Rodriguez de Fonseca, MD, PhD
    CSO

    Leading investigator in the Cannabinoid System, Feeding and Addiction Behavioral Disorders.
    Principal Investigator and Head of Neuropsychopharmacology research programs at IBIMA Research centre (Malaga Hospital System). "Nicolas Monardes" Senior Chair in Research.
    Head of Neuropsychopharmacology research group, Complutense University, School of Psychology (Madrid).
    297 published scientific articles.
    21 patents granted.
    71 research grants awarded

Advisors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free